on The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Holdings in Avadel Pharmaceuticals
The Vanguard Group, Inc. made a disclosure under Rule 8.3 of the Irish Takeover Panel Act, 1997. The document details Vanguard's interests in Avadel Pharmaceuticals plc. As of February 4, 2026, Vanguard holds 5,790,386 US$0.01 ordinary shares of Avadel, representing a 5.94% stake.
In recent transactions, Vanguard purchased 2,071 shares and sold 576 shares, both at a price of 21.57 USD per share. These transactions pertain solely to US$0.01 ordinary shares, as there are no disclosed dealings in derivatives or options tied to Avadel securities.
The disclosure also confirmed no involvement in any indemnity or other strategic arrangements related to Avadel securities. Additionally, there are no agreements regarding voting rights or acquisitions tied to derivatives.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news